Abstract
Adenoviral vectors are a popular choice for gene transfer protocols because they are well characterized, have a relatively large cloning capacity (up to 36 kB), and can be grown to high titers (1013 particles/mL) (1). Despite these attributes, first-generation adenoviral vectors retain many viral genes that can elicit a strong immune response, severely limiting their utility for studies in vivo (2). Our laboratory and others have been developing “gutted” or helper-dependent adenoviruses, which lack all viral coding sequences and therefore should greatly enhance the persistence of the vector in vivo (3,4). We have used this technology to deliver to muscle full-length cDNAs of the largest known gene, dystrophin, under control of the mouse muscle creatine kinase enhancer plus promoter (4–6).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Graham, F. L. and Prevec, L. (1991) Manipulation of Adenovirus Vectors, in Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. (Murray, E. J., ed.), Humana, Totowa, pp. 109–128.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E., and Wilson, J. M. (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407–4411.
Kochanek, S., Clemens, P. R., Mitani, K., Chen, H.-H., Chan, S., and Caskey, C. T. (1996) A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731–5736.
Kumar-Singh, R. and Chamberlain, J. S. (1996) Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5, 913–921.
Dello Russo, C, Scott, J., Hartigan-O’Connor, D., et al. (2002) Functional reversal of dystrophy in adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. In press.
Hauser, M. A., Amalfitano, A., Kumar-Singh, R., Hauschka, S. D. and Chamberlain, J. S. (1997) Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromusc. Disord. 7, 277–283.
Temperley, S. M. and Hay, R. T. (1992) Recognition of the adenovirus type 2 origin of DNA replication by the virally encoded DNA polymerase and preterminal proteins. EMBO J. 11, 761–768.
Schaack, J., Ho, W. Y., Freimuth, P., and Shenk, T. (1990) Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev. 4, 1197–1208.
Grable, M. and Hearing, P. (1990) Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J. Virol. 64, 2047–2056.
Bett, A. J., Prevec, L., and Graham, F. L. (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67, 5911–5921.
Parks, R. J. and Graham, F. L. (1997) A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 71, 3293–3298.
Barjot, C., Hartigan-O’Connor, D. O., Scott, J. M., Salvatori, G., and Chamberlain, J. S. (2002) Packaging cell lines for gutted adenoviral vector growth using E1, E2b, and E3-deleted helper viruses. In press.
Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–72.
Amalfitano, A., Begy, C. R., and Chamberlain, J. S. (1996) Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA 93, 3352–3356.
Amalfitano, A. and Chamberlain, J. S. (1997) Isolation and characterization of packaging cell lines that co-express the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther. 4, 258–263.
Hartigan-O’Connor, D., Amalfitano, A., and Chamberlain, J. S. (1999) Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J. Virol. 73, 7835–7841.
Hartigan-O’Connor, D., Barjot, C., Crawford, R. and Chamberlain, J. (2002) Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection. Hum. Gene Ther. 13, 519–531.
Gerard, R. D. and Meidell, R. S. (1995) Adenovirus vectors, in DNA Cloning: a Practical Approach. (Hames, B., and Glover, D., eds.), Oxford University Press, Oxford, pp. 285–307.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Mittereder, N., March, K. L., and Trapnell, B. C. (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498–7509.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Scott, J.M., Chamberlain, J.S. (2003). Gutted Adenoviral Vectors for Gene Transfer to Muscle. In: Metzger, J.M. (eds) Cardiac Cell and Gene Transfer. Methods in Molecular Biology, vol 219. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-350-X:19
Download citation
DOI: https://doi.org/10.1385/1-59259-350-X:19
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-994-0
Online ISBN: 978-1-59259-350-7
eBook Packages: Springer Protocols